cMYc targeting ribosome modulating agent - Eloxx Pharmaceuticals
Latest Information Update: 30 Nov 2023
At a glance
- Originator Eloxx Pharmaceuticals
- Class Antineoplastics; Small molecules
- Mechanism of Action Ribosomal RNA modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 30 Nov 2023 Discontinued for Cancer in Israel (unspecified route) (Eloxx Pharmaceuticals pipeline, November 2023)
- 09 Aug 2023 Early research in Cancer in Israel (unspecified route) (before August 2023) (Eloxx Pharmaceuticals Pipeline, August 2023)